Elliott L. Fineman
Directeur Général chez Planet Biotechnology, Inc.
Profil
Elliott L.
Fineman is the founder of SuperGen, Inc. founded in 1991.
He is currently the President & Chief Executive Officer at Planet Biotechnology, Inc. since 1998.
He previously worked as the Chief Operating Officer at SuperGen, Inc. and as a Principal at Cetus Corp.
Mr. Fineman has an undergraduate degree from Oberlin College, a graduate degree from the University of Baltimore, and another graduate degree from Georgetown University.
Postes actifs de Elliott L. Fineman
| Sociétés | Poste | Début |
|---|---|---|
Planet Biotechnology, Inc.
 Planet Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Planet Biotechnology, Inc. identifies and develops promising antibodies and receptor-antibody fusion molecules for the treatment and prevention of infectious diseases including emerging diseases and bio-threat agents. The company was is headquartered in Hayward, CA. | Directeur Général | 01/01/1998 |
Anciens postes connus de Elliott L. Fineman
| Sociétés | Poste | Fin |
|---|---|---|
SuperGen, Inc.
 SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Fondateur | 13/09/2011 |
| Cetus Corp. | Corporate Officer/Principal | - |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Directeur des opérations | - |
Formation de Elliott L. Fineman
| Oberlin College | Undergraduate Degree |
| University of Baltimore | Graduate Degree |
| Georgetown University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Health Technology |
Planet Biotechnology, Inc.
Planet Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Planet Biotechnology, Inc. identifies and develops promising antibodies and receptor-antibody fusion molecules for the treatment and prevention of infectious diseases including emerging diseases and bio-threat agents. The company was is headquartered in Hayward, CA. | Health Technology |
| Cetus Corp. | Health Technology |